Professional Documents
Culture Documents
Presentation File
Presentation File
Executive Summary
Pre-IPO Investment Opportunity
Steve Woody
David Fann
Joe McGuire
Paul Cox
What is Theraworx?
Disruptive: An innovation that creates a new market by applying a different set of values
which ultimately (and unexpectedly) takes over an existing market. Source: wikipedia
New Drugs
Few New Antibiotic Drugs Are Slated for Release
Drugs Cant be Approved Fast Enough to Keep up with Emerging Diseases
Proliferation of Drug Consumption Only Exacerbates the Issue
Government
Agencies
Healthcare
Providers
A Breakthrough Discovery
GRAM (-)
BACTERIA
SKIN
NON-TOXIC
WOUNDS
BROAD
SPECTRUM
ACTIVITY
BROAD
SPECTRUM
ACTIVITY
NON-TOXIC
MUCOUS
MEMBRANE
GRAM (+)
BACTERIA
YEAST
FUNGI
VIRUSES
Ebola Studies:
Texas Biomedical Research Institute
CDC Study of Efficacy of Theraworx in Liberia
STRATUM
CORNEUM
MANAGEMENT
PERINEUM
FACE
Launched
Catheter
Care
Long Term
Care
Launch In Process
ICU Bathing
Catheter Care
ICU
Bathing
MRSA
Decolonization
Burn and
Trauma
Care
Urine
Analysis
Chronic
Wound Care
Clinical
Applications
2015 Launch
Urine Analysis Kit
Pediatric ICU Bathing
2016 Launch
Burn Patient Care
MRSA Decolonization
Consumer
Government
International:
Government:
Domestic Leverage relationship with leading distributor, ADS, and General Gale Pollock to U.S.
Government to promote Combat One.
International Leverage relationship with the RPT Consulting who has established ties to multiple
international governments
Consumer:
Manufacturing Capabilities
Manufactured in Asheville, NC
Corporate Milestones
Milestones
2007
Avadim LLC Formed
Licensed Theraworx
2008-2012
Clinical Trials
2013-2014
Purchased Theraworx
Launched Sales team
Formed Avadim
Technologies, Inc.
Filed Three Patents
Launched Consumer Brands
2015
Revenue Projections
2014 Sales Revenue
120000000
$400,000
100000000
$350,000
$300,000
80000000
$250,000
Revenue
60000000
$200,000
Gross Profit
Net Income
$150,000
40000000
*Estimated
$100,000
20000000
$50,000
$0
JAN
Revenue
Gross Profit
Gross Profit Percentage
Net Income
2015
2016
2017
2012
2013
2014
2015 2016
2017
.20M
0.24M
1.4M
16.3M
48.0M
96.4M
.06M
0.09M
0.9M
11.3M
33.2M
66.7M
30%
38%
64%
69%
69%
69%
-.41M
-1.13M
-1.3M
2.9M
9.1M
19.9M
Pet
Clinical
$200M
$50M
One Science....
International
$200M
Avadim
$750M
Sports
$100M
Cosmetic
$200M
Multiple Solutions.
Capitalization
Infrastructure
Sales
$5M PPM
IPO
Valuation
Valuation based on Enterprise Value times Forward Sales Model- Industry Standard
Harvard-MIT Study 352 M&A Transactions
Valuation
Market Cap
Revenues
$1,600,000,000
$37.50
$12,000,000
$1,400,000,000
$10,000,000
$1,200,000,000
$8,000,000
$1,000,000,000
$19.08
$800,000,000
$6,000,000
$600,000,000
$4,000,000
$9.00
$400,000,000
$6.84
$200,000,000
$2.59
$2,000,000
$4.32
$0
$0
3/31/2015
Revenues*
Market Cap*
Stock Price*
6/30/2015
3/31/2015
$676,000
$103,400,000
$2.59
9/30/2015
6/30/2015
$1,200,000
$172,800,000
$4.32
12/31/2015
9/30/2015
$1,900,000
$273,600,000
$6.84
12/31/2016
12/31/2015
$2,500,000
$360,000,000
$9.00
*Revenues, Market cap, and stock price are projected estimates and are not guaranteed.
12/31/2017
12/31/2016
$5,300,000
$763,200,000
$19.08
12/31/2017
$10,400,000
$1,500,000,000
$37.50
Growth of Sports Medicine Line- Innergy Sport (i.e. Test from University South Carolina to be issued)
Growth of Acne Product Line
Growth of Personal Protection for the T-Zone - TheraZone
A synergistic buyer who applies the investment standard of measuring our business value. Such buyers are often willing to pay a premium for a business
because they can realize some unique advantages through a business purchase. We have been approached by four multi-billion companies in 2014.
Patented Technology
Clinically Validated
Clinically Accepted
Disruptive Technology
Proven Multi-Market
High
Growth
Model
Proven
Technology
Why
Invest
Global Outreach
Giving Back
Eblen Partnership
World Health Organization
Serving Others
Saving
Lives
Government Mandate
70% Gross Profit Model
Multiple Revenue Streams
Global Expansion
Recurring Revenue Model
Use of Proceeds:
Sales and Marketing ($1.4M)
Working Capital ($1.2M)
Launch of New Products
New Patent Applications
Manufacturing Upgrade
NDA)
$3B Catheter Company
$5B Consumer and Medical Revenue Company
$10B Medical Products
$2B Global Medical Company
Contact Information
Joe McGuire
joe@theraworx.com
904.228.2603
David Fann
david@theraworx.com
904.251.4910
Paul Cox
paulcox@pilotagecc.com
604-689-0037